还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

, q3 q  x: }9 ]. C                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

) _, {+ T% v7 l, m: Y: ?) j可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
2 }) x- [6 q6 ^  d# }

Sub-category:
Molecular Targets

! ]1 S3 X  B% ^; I9 Y7 d7 I0 N# J
Category:
Tumor Biology
9 j7 O; Y5 d8 a

0 q! F" G& k  E: nMeeting:
. N) J/ L' y( g$ v' C' o2011 ASCO Annual Meeting
- w# N$ G; {/ Q8 c0 c
4 W/ [1 c) G7 x2 q
; h. O7 W  D3 n2 \8 C/ c) QSession Type and Session Title:
6 x* S4 Y2 s1 g& K" V" J/ MPoster Discussion Session, Tumor Biology


* g! F' \/ Z1 K) K3 W2 vAbstract No:
- g. \: r2 e0 r) @9 E- G10517


* |* E+ i5 X+ y1 ~, a9 SCitation:
' {3 @9 c& i: R1 D; X; z% ^J Clin Oncol 29: 2011 (suppl; abstr 10517)
6 |/ s# x. `, ~! R

) Q5 ]( b! P1 e+ s8 W9 yAuthor(s):
( T* W; q6 n# n3 O. p- W$ KJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


8 U5 F, u, ?3 [8 o, P- C" ]* T
7 d5 d$ |) V6 N, m0 SAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ @: [6 {5 \6 o2 q( g! i& L
7 `! {( q& D% i  h2 y$ gAbstract Disclosures
$ K* l8 r1 B5 B, J: u- I
* ?* u' @  t+ k* H1 d1 aAbstract:
7 L% v1 D6 F4 L
# h; a$ C" n7 M, }! u
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.


' |$ `0 P+ {6 M- x0 k; j

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
- D6 b3 H9 G5 K: ?9 D
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊